Saturday, December 17, 2011 1:49:12 PM
I respectfully disagree with you on your stance. Yes, government officials and CEOs of companies have a right to keep there constituents and shareholders informed. When they are allowed, and what they are allowed to say are two very different things. The details of ongoing deals can be guarded for a period of time before being disclosed to the public. Do you honestly think any company is going to answer a random caller's questions? Do you really think that DR government officials are going to tell you all about details of a track proposal, because you are invested in a company involved in the proposal? We are taking about a country known for having extreme corruption within its ranks.
My point is it is extremely foolish to think you can call random people up, ask about dealings with the DR government and CGAQ, and expect to get an answer that has any added value. That is like asking the cashier at McDonalds where the company plans to open the next franchise.
I work for the US government. That doesn't mean I 'know' everything going on all over the place. Plus, if I am working with a proposal between the DoD and a private company I would never disclose information about it to a random caller unless I felt like getting fired and/or going to jail. It is ridiculous to think it would work any different.
Swank has a responsibility to represent the best interest' of investors. It does NOT mean that he has to submit to every demand. The DR government does NOT have to do anything for an investor, or Swank for that matter.
My point is it is extremely foolish to think you can call random people up, ask about dealings with the DR government and CGAQ, and expect to get an answer that has any added value. That is like asking the cashier at McDonalds where the company plans to open the next franchise.
I work for the US government. That doesn't mean I 'know' everything going on all over the place. Plus, if I am working with a proposal between the DoD and a private company I would never disclose information about it to a random caller unless I felt like getting fired and/or going to jail. It is ridiculous to think it would work any different.
Swank has a responsibility to represent the best interest' of investors. It does NOT mean that he has to submit to every demand. The DR government does NOT have to do anything for an investor, or Swank for that matter.
Recent BSEM News
- BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026 • GlobeNewswire Inc. • 04/08/2026 11:00:00 AM
- BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2026 08:05:00 PM
- BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025 • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
- BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/24/2026 08:05:00 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 03:40:56 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026 • GlobeNewswire Inc. • 03/11/2026 08:05:00 PM
- BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference • GlobeNewswire Inc. • 02/20/2026 12:00:00 PM
- BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business • GlobeNewswire Inc. • 01/21/2026 10:30:00 PM
- BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 01/07/2026 09:05:00 PM
- BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 12/18/2025 12:00:00 PM
- BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference • GlobeNewswire Inc. • 12/10/2025 12:00:00 PM
- BioStem Technologies Expands Product Access in Medicaid • GlobeNewswire Inc. • 11/25/2025 01:59:13 PM
- BioStem Technologies Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/13/2025 09:02:00 PM
- BioStem Technologies Announces Filing of Restated Financial Statements • GlobeNewswire Inc. • 11/13/2025 09:01:00 PM
- BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes • GlobeNewswire Inc. • 11/05/2025 09:05:00 PM
- BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters • GlobeNewswire Inc. • 11/05/2025 12:00:00 PM
- BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers • GlobeNewswire Inc. • 10/31/2025 11:00:00 AM
- BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025 • GlobeNewswire Inc. • 10/30/2025 08:05:00 PM
- BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant • GlobeNewswire Inc. • 10/27/2025 08:15:00 PM
- BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program • GlobeNewswire Inc. • 10/02/2025 04:00:00 PM
